You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

INOVIO prices public offering of approximately USD75m

First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer

Elicera Therapeutics secures Chinese patent allowance for ELC-401

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

Pentixapharm advances preparationsfor Phase 3 PANDA study

CStone and Kimia Therapeutics collaborate to advance oncology drug candidate

Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia

Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial

INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP

Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101

TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights

Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme

Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial

Novocure and Verastem to evaluate combination therapy for pancreatic cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026